Movatterモバイル変換

[0]ホーム
URL:

Jump to content
WikipediaThe Free Encyclopedia
Search

Imidafenacin

From Wikipedia, the free encyclopedia
Chemical compound
Pharmaceutical compound
Imidafenacin
Clinical data
Routes of
administration		By mouth
ATC code
Legal status
Legal status
  • In general: ℞ (Prescription only)
Identifiers
  • 4-(2-Methyl-1H-imidazol-1-yl)-2,2-diphenylbutanamide
CAS Number
PubChemCID
ChemSpider
UNII
ChEMBL
CompTox Dashboard(EPA)
ECHA InfoCard100.216.585Edit this at Wikidata
Chemical and physical data
FormulaC20H21N3O
Molar mass319.408 g·mol−1
3D model (JSmol)
  • CC1=NC=CN1CCC(C2=CC=CC=C2)(C3=CC=CC=C3)C(=O)N
  • InChI=1S/C20H21N3O/c1-16-22-13-15-23(16)14-12-20(19(21)24,17-8-4-2-5-9-17)18-10-6-3-7-11-18/h2-11,13,15H,12,14H2,1H3,(H2,21,24) ☒N
  • Key:SQKXYSGRELMAAU-UHFFFAOYSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

Imidafenacin (INN) is aurinaryantispasmodic of theanticholinergic class.[1] It is used for the treatment ofurinary incontinence and related bladder issues, especially in patients withbenign prostatic hyperplasia or who have had prostate surgery. Unlike most related drugs, it is orally active but still shows a rapid onset of action, which makes it more convenient to administer.[2][3][4]

References

[edit]
  1. ^Kobayashi F, Yageta Y, Segawa M, Matsuzawa S (2007). "Effects of imidafenacin (KRP-197/ONO-8025), a new anti-cholinergic agent, on muscarinic acetylcholine receptors. High affinities for M3 and M1 receptor subtypes and selectivity for urinary bladder over salivary gland".Arzneimittelforschung.57 (2):92–100.doi:10.1055/s-0031-1296589.PMID 17396619.S2CID 21636454.
  2. ^Mostafaei H, Salehi-Pourmehr H, Jilch S, Carlin GL, Mori K, Quhal F, Pradere B, Grossmann NC, Laukhtina E, Schuettfort VM, Aydh A, Sari Motlagh R, König F, Roehrborn CG, Katayama S, Rajwa P, Hajebrahimi S, Shariat SF (Jul 2022). "Choosing the Most Efficacious and Safe Oral Treatment for Idiopathic Overactive Bladder: A Systematic Review and Network Meta-analysis".Eur Urol Focus.8 (4):1072–1089.doi:10.1016/j.euf.2021.08.011.PMID 34563481.
  3. ^Su YT, Chen HL, Teoh JY, Chan VW, Wu WJ, Lee HY (Oct 2023)."Comparison of add-on medications for persistent storage symptoms after α-blocker treatment in BPH patients - a network meta-analysis".BMC Urol.23 (1) 154.doi:10.1186/s12894-023-01327-1.PMC 10546657.PMID 37789333.
  4. ^Lee JH, Goh HJ, Lee K, Choi DW, Lee KM, Kim S (Sep 2024)."Efficacy and safety evaluation of imidafenacin administered twice daily for continency recovery following radical prostatectomy in prostate cancer patients: Prospective open-label case-controlled randomized trial".Investig Clin Urol.65 (5):466–472.doi:10.4111/icu.20240129.PMC 11390266.PMID 39249919.
Urologicals, including antispasmodics (G04B)
Acidifiers
Urinaryantispasmodics
(primarilyantimuscarinics)
Other urologicals
mAChRsTooltip Muscarinic acetylcholine receptors
Agonists
Antagonists
Precursors
(andprodrugs)
Stub icon

Thisdrug article relating to thegenito-urinary system is astub. You can help Wikipedia byadding missing information.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Imidafenacin&oldid=1332187686"
Categories:
Hidden categories:
[8]ページ先頭
©2009-2026 Movatter.jp